EFCCA´s new working methodology aims to identify and address the real needs of patients with Crohn’s disease and Ulcerative Colitis, also collectively known as Inflammatory Bowel Disease (IBD).
The working methodology is based on the concept of analysing and interpreting scientific data in order to improve therapeutic outcomes. EFCCA’s approach is called DIVA (Data Insights for Added therapeutic VAlue) which will make use of publicly available data as well as internal EFCCA data to analyse and interpret the IBD patient communities’ unmet needs.
DIVA will also provide harmonised opinions and recommendations to stakeholders such as regulators, policy makers, pharmaceutical industries and healthcare professionals. At EFCCA we believe that the patient should be the starting point in the diagnosis and treatment of IBD.
How to access DIVA?
Currently DIVA’s platform can be accessed by EFCCA members only. Other stakeholders can receive reports on request. DIVA is still in the pilot phase, EFCCA and its members will further disicuss criteria for partial access to the DIVA platform of non-member stakeholders.
For more info please write to: email@example.com
Download information leaflet